Literature DB >> 15866240

Multi-faceted strategies to combat disease by interference with the chemokine system.

Zoë Johnson1, Matthias Schwarz, Christine A Power, Timothy N C Wells, Amanda E I Proudfoot.   

Abstract

Inappropriate cell recruitment is a hallmark of all autoimmune, allergic and inflammatory diseases. The prevention of inflammation by interfering with cellular recruitment through the neutralization of cytokines and adhesion molecules has proven to be successful in the clinic. Chemokines are important potential targets owing to their central role in the cell recruitment process. Chemokines are unique among cytokines because they signal through seven transmembrane receptors, thus enabling the identification of small molecule inhibitors through high throughput screening. The object of this Review is to discuss the validity and feasibility of targeting several points of therapeutic intervention offered by the chemokine system and to assess the state of play within the field to date.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866240     DOI: 10.1016/j.it.2005.03.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  25 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

Review 2.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

Review 3.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 4.  Chemokines in inflammatory bowel disease.

Authors:  S Danese; A Gasbarrini
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 5.  Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Authors:  Martin Stangel; Corinna Trebst
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

6.  The green tea polyphenol (-)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR.

Authors:  Jingjing Zhu; Oumei Wang; Lingfei Ruan; Xinwei Hou; Youhong Cui; Ji Ming Wang; Yingying Le
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

Review 7.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

8.  Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease.

Authors:  Miquel Sans; Silvio Danese; Carol de la Motte; Heitor S P de Souza; Brenda M Rivera-Reyes; Gail A West; Manijeh Phillips; Jeffry A Katz; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2006-10-12       Impact factor: 22.682

9.  Downregulation of CX3CR1 ameliorates experimental colitis: evidence for CX3CL1-CX3CR1-mediated immune cell recruitment.

Authors:  Felix Becker; Christina Holthoff; Christoph Anthoni; Emile Rijcken; J Steven Alexander; Felicity N E Gavins; H U Spiegel; Norbert Senninger; Thorsten Vowinkel
Journal:  Int J Colorectal Dis       Date:  2016-12-10       Impact factor: 2.571

10.  Therapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reaction.

Authors:  Miriam Canavese; Fiorella Altruda; Lorenzo Silengo
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.